Genoa Ventures

Genoa Ventures invests under a 'Biology by Design' thesis, targeting platform companies at the intersection of biology and computation, synthetic biology, lab automation, and AI-driven drug discovery. The firm treats biology as an engineering discipline and seeks companies whose core intellectual property is a proprietary dataset and a computational loop that improves biological outputs over time. This distinguishes Genoa from life sciences investors focused on single-asset therapeutic plays.

Genoa focuses on early-stage investments, typically leading or co-leading seed and Series A rounds. The firm has also demonstrated willingness to incubate companies alongside scientific founders at the pre-formation stage. Portfolio companies tend to be platforms with broad market applicability rather than single-product startups.

The firm's primary sector concentrations are AI/ML-driven life sciences, lab automation, synthetic biology, computational drug discovery, and digital health platforms. Investment priorities favor companies where software and data science are as central to the value proposition as the underlying biological science.

Genoa operates as a lead or co-lead investor in its rounds and collaborates with crossover funds and specialist life sciences investors with deep domain expertise. The firm's syndication approach reflects the technical complexity of its portfolio — co-investors are typically selected for their ability to diligence computationally intensive biology platforms.

Genoa Ventures is headquartered in San Francisco, California. The firm invests across North America and Europe, with a particular concentration in life sciences and computational biology talent hubs — principally the Bay Area, Boston, and London.